NIDA Notes keeps you up to date on research advances in the causes, consequences, prevention, and treatment of drug abuse and addiction and HIV/AIDS.
Learn more about NIDA Notes
Describes investigations to advance the development of potential drug abuse relapse prevention agents by targeting specific receptors of the neurochemical serotonin.
Reports on the research underway to identify gene variations associated with nicotine addiction and the interaction of genetic makeup, experiences, and surroundings to addiction.
Describes research on a vaccine developed to facilitate smoking cessation by blocking nicotine penetration into the brain.
Reports findings from a clinical trial investigating the effectiveness of naltrexone as a supplement to nicotine replacement therapy for smoking cessation.
Describes a meeting of researchers and clinicians who gathered to discuss the challenges in balancing appropriate pain treatment with efforts to minimize prescription opioid misuse.
Describes a study comparing Staged Care Intervention, a combination treatment for smoking cessation, among smokers in outpatient treatment for depression and a control group.
Reports on a study to investigate the use of methadone maintenance for heroin addicts wait-listed for a treatment program to encourage their likelihood to enroll in the program.
Reports on research that successfully traced rats’ liking for sweets to a 1-cubic millimeter site in the medial shell of the nucleus accumbens in the brain.
Announces the recipient of a 2006 award for innovation in research on drug addiction and alcoholism, Dr. Yavin Shaham, and describes his research which focused on the stress-induced drug use relapse.
Announces updates to research reports on MDMA/ecstasy and steroids and a new report on HIV/AIDS that provide the latest available information on drugs and drug-related topics.
Testing a Prospective Medication To Help People Avoid Relapse
The Rise and Fall of the Cocaine High
Electronic Tools for Use in the Continuum of Care for Patients With Addiction
Researchers Speak: Dr. Thomas Kosten